TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10347395

Group type: EXPERIMENTAL
Intervention: Special Intervention (group nutrition education classes)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Special Intervention (individual self-paced nutrition education program)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Usual Care (control group receiving usual nutrition education)
Number of subjects: 502
Study: 7498042

Group type: EXPERIMENTAL
Intervention: Trapezoidal flap (TF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Semilunar flap (SF)
Number of subjects: 20
Study: 1712524

Group type: EXPERIMENTAL
Intervention: ERU capsules (Radicis urticae) for 7 days
Number of subjects: 2

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 2
Study: 7002338

Group type: EXPERIMENTAL
Intervention: Group 1: 5656 rads in 28 fractions in 5 1/2 weeks (202 rads daily)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Group 2: 4352 rads in 12 unequal fractions in 4 weeks (294 rads each Monday and Wednesday and 500 rads on Fridays)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Group 3: 4352 rads in 12 unequal fractions in 4 weeks with 3 g/m2 oral misonidazole 4 hours before the 500-rad fraction, once a week for 4 weeks
Number of subjects: 55
Study: 31578113

Group type: EXPERIMENTAL
Intervention: Early video capsule
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 87
Study: 28921841

Group type: EXPERIMENTAL
Intervention: Dietary protein restriction (PR) for one month
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet for one month
Number of subjects: 0
Study: 25860126

Group type: EXPERIMENTAL
Intervention: Carbetocin (20 µg to 140 µg, adjusted based on previous patient's response)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Carbetocin (140 µg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Carbetocin (not specified)
Number of subjects: 40
Study: 24054343

Group type: EXPERIMENTAL
Intervention: Autonomic regulation therapy (ART)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vagal nerve stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 21377144

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment for insomnia for AD (CBTI-AD, n=9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Behavioral placebo treatment (BPT, n=8)
Number of subjects: 17
Study: 19614786

Group type: EXPERIMENTAL
Intervention: Saxagliptin 2.5 mg
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg
Number of subjects: 768

Group type: COMPARATOR
Intervention: Uptitrated glyburide (10 mg to 15 mg)
Number of subjects: 768
Study: 16763053

Group type: EXPERIMENTAL
Intervention: Endoscopic gastroplication
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 60

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 60
Study: 15285300

Group type: EXPERIMENTAL
Intervention: Comprehensive information leaflet and reminder letters
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard basic information
Number of subjects: 500
Study: 11336663

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9624484

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin-vancomycin
Number of subjects: 84
Study: 8080747

Group type: EXPERIMENTAL
Intervention: Chemotherapy response (complete response, partial response, stable disease)
Number of subjects: 324
Study: 2975491

Group type: EXPERIMENTAL
Intervention: Standard dose of HBV vaccine (5 micrograms)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Reduced dose of HBV vaccine (2 micrograms)
Number of subjects: 40
Study: 30921795

Group type: EXPERIMENTAL
Intervention: 3 weeks of spa therapy (group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2 weeks of spa therapy (group 2)
Number of subjects: 60
Study: 27359182

Group type: EXPERIMENTAL
Intervention: DVD-delivered exercise intervention (FlexToBa)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Attentional control DVD condition focused on healthy aging
Number of subjects: 307
Study: 26499146

Group type: EXPERIMENTAL
Intervention: Peritoneal chemotherapy with Lobaplatin (40 mg intraoperatively) followed by intravenous FOLFOX regimen
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group receiving only FOLFOX regimen
Number of subjects: 103
Study: 23341353

Group type: EXPERIMENTAL
Intervention: Participants receiving additional information about the screening programme
Number of subjects: 2059

Group type: COMPARATOR
Intervention: Non-participants receiving additional information
Number of subjects: 2059
Study: 21325456

Group type: EXPERIMENTAL
Intervention: Bariatric surgery women
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Bariatric surgery women in summer
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Bariatric surgery women in winter
Number of subjects: 98
Study: 19207894

Group type: EXPERIMENTAL
Intervention: Implants with internal sinus lift (ISL) without graft material
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (native posterior maxilla implants)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Implants with ISL
Number of subjects: 36
Study: 17559913

Group type: EXPERIMENTAL
Intervention: Ecallantide (5, 10, 20, or 40 mg/m² intravenously)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 15040783

Group type: EXPERIMENTAL
Intervention: PMD3117 (Ang I vaccine)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Aluminium hydroxide (Alhydrogel)
Number of subjects: 27
Study: 11828273

Group type: EXPERIMENTAL
Intervention: HRT with estradiol valerate and cyproterone acetate (Pausene(R))
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cacit Vitamin D30(R) (Control Group)
Number of subjects: 100
Study: 9658688

Group type: EXPERIMENTAL
Intervention: In situ teicoplanin treatment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Empirical amikacin therapy switched to teicoplanin
Number of subjects: 12
Study: 7709042

Group type: EXPERIMENTAL
Intervention: Thymostimulin
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Beta IFN
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Thymostimulin + Beta IFN
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 48
Study: 2649462

Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO; 11 g/m2)
Number of subjects: 626

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 626
Study: 322546

Group type: EXPERIMENTAL
Intervention: Intravenous diazepam 2.5 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Intravenous diazepam 5 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Intravenous diazepam 10 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Intravenous diazepam 20 mg
Number of subjects: 140
Study: 30407270

Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 344

Group type: COMPARATOR
Intervention: Internet-based exercise program
Number of subjects: 344
Study: 27814282

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sham remote ischemic preconditioning (sRIPC)
Number of subjects: 51
Study: 25948027

Group type: EXPERIMENTAL
Intervention: Pharmacologic Group (IV infusion of ephedrine 37.5 mg/h)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non‐Pharmacologic Group (15° left lateral tilt)
Number of subjects: 36
Study: 22954665

Group type: EXPERIMENTAL
Intervention: sorafenib (400mg, orally, twice daily) plus paclitaxel (90mg/m(2), weekly, intravenously, 3 weeks on/1 week off)
Number of subjects: 220

Group type: COMPARATOR
Intervention: placebo plus paclitaxel (90mg/m(2), weekly, intravenously, 3 weeks on/1 week off)
Number of subjects: 220
Study: 21320086

Group type: EXPERIMENTAL
Intervention: GlideRite® nasal tracheal tube
Number of subjects: 110

Group type: COMPARATOR
Intervention: pre‐rotated RAE™ nasal tracheal tube
Number of subjects: 110
Study: 19186715

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment using acupoint group I (BL 15, BL 18, BL 20, BL 23) and acupoint group II (CV 4, CV 3, SP 6, KI 3, LR 3)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Medication treatment with Sailete tablets, 20 mg each tablet, one tablet each night
Number of subjects: 111
Study: 16984495

Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.d. for 7 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 14986209

Group type: EXPERIMENTAL
Intervention: Blue-on-yellow (B/Y) perimetry
Number of subjects: 80

Group type: COMPARATOR
Intervention: White-on-white (W/W) perimetry
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal values from Twinfield Perimeter
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 80
Study: 11131626

Group type: EXPERIMENTAL
Intervention: Walking with forearm crutches
Number of subjects: 19
Study: 9102058

Group type: EXPERIMENTAL
Intervention: Calcium supplement group (n = 14, mean calcium intake 1988 +/- 90 mg/day)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (n = 21, mean calcium intake 952 +/- 109 mg/day)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Non-compliant group (n = 49, mean calcium intake 981 +/- 75 mg/day)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 84
Study: 7689519

Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 115
Study: 3736025

Group type: EXPERIMENTAL
Intervention: Alternate forms of the Peabody Picture Vocabulary Test (PPVT)
Number of subjects: 154
Study: 31533717

Group type: EXPERIMENTAL
Intervention: Patient web portal usage
Number of subjects: 7749

Group type: EXPERIMENTAL
Intervention: Knowing DXA test results
Number of subjects: 7749

Group type: EXPERIMENTAL
Intervention: Characteristics of web portal users
Number of subjects: 7749

Group type: EXPERIMENTAL
Intervention: Overall patient awareness of test results
Number of subjects: 7749
Study: 29133605

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 3642
Study: 26059390

Group type: EXPERIMENTAL
Intervention: Paro (companion robot)
Number of subjects: 37
Study: 24844389

Group type: EXPERIMENTAL
Intervention: d‐PTFE membranes
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no membranes)
Number of subjects: 15
Study: 22549115

Group type: EXPERIMENTAL
Intervention: Citalopram plus pioglitazone (15 mg every 12 h)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Citalopram plus placebo
Number of subjects: 40
Study: 20338030

Group type: EXPERIMENTAL
Intervention: Hand-assisted retroperitoneoscopic donor nephrectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard laparoscopic donor nephrectomy
Number of subjects: 0
Study: 18848141

Group type: EXPERIMENTAL
Intervention: 75 mg azimilide
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: 125 mg azimilide
Number of subjects: 633

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 633
Study: 15088872

Group type: EXPERIMENTAL
Intervention: Periodontal probes (4 different types)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Scanning electron microscopy (SEM) examination of probe tips
Number of subjects: 8
Study: 11755322

Group type: EXPERIMENTAL
Intervention: Ketamine 1 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg followed by an infusion of 6-10 mg/kg.hr(-1))
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (air/oxygen/isoflurane anesthesia)
Number of subjects: 30
Study: 10193349

Group type: EXPERIMENTAL
Intervention: rhuMAb‐E25
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 8000128

Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Iodinated contrast material
Number of subjects: 32
Study: 3178440

Group type: EXPERIMENTAL
Intervention: Immediate mobilization (group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Plaster immobilization (group B)
Number of subjects: 20
Study: 1092585

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bethanechol 25 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 28195970

Group type: EXPERIMENTAL
Intervention: Cooling vest (COOL)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 10
Study: 28786919

Group type: EXPERIMENTAL
Intervention: Intervention A (improving community participation in vector control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intervention B (ultra-low volume (ULV) spraying)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both interventions (A and B)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intervention A
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intervention B
Number of subjects: 24
Study: 26135593

Group type: EXPERIMENTAL
Intervention: Intravenous levetiracetam 1500 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral levetiracetam 1500 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Multiple-dose intravenous levetiracetam 1500 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 100
Study: 23839771

Group type: EXPERIMENTAL
Intervention: CSMD1 risk 'A' allele
Number of subjects: 150
Study: 21447413

Group type: EXPERIMENTAL
Intervention: High dietary vitamin K intake
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Increase in dietary vitamin K intake
Number of subjects: 365

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 365
Study: 18419721

Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg IV intra-operatively with parecoxib 40 mg IV during surgery and valdecoxib 40 mg PO for 7 days
Number of subjects: 160

Group type: COMPARATOR
Intervention: Paracetamol 1 g IV during surgery and 1 g PO for 7 days
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg IV during surgery and valdecoxib 40 mg PO for 7 days
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg IV intra-operatively with paracetamol 1 g IV during surgery and 1 g PO for 7 days
Number of subjects: 160
Study: 16981923

Group type: EXPERIMENTAL
Intervention: RVA pacing >50% of the time (pacing group, n=46)
Number of subjects: 76

Group type: COMPARATOR
Intervention: RVA pacing <50% of the time (sensing group, n=30)
Number of subjects: 76
Study: 14513808

Group type: EXPERIMENTAL
Intervention: 10 mg dose of finasteride
Number of subjects: 20
Study: 10837942

Group type: EXPERIMENTAL
Intervention: Hypofractionated stereotactic radiotherapy (HSRT)
Number of subjects: 32
Study: 9265936

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 2.3% end-tidal concentration
Number of subjects: 30
Study: 8314483

Group type: EXPERIMENTAL
Intervention: 3 million units interferon (IFN) alfa‐2b three times a week for three months
Number of subjects: 0

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3 million units interferon (IFN) alfa‐2b
Number of subjects: 0
Study: 3514204

Group type: EXPERIMENTAL
Intervention: Vigabatrin (GVG) 3 g/day
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Vigabatrin (GVG)
Number of subjects: 19
Study: 28464434

Group type: EXPERIMENTAL
Intervention: Pilates exercise program (G1)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Electrical stimulation combined with PFMT (G2)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (G3)
Number of subjects: 123
Study: 27990435

Group type: EXPERIMENTAL
Intervention: Supraclavicular brachial plexus block with 20 mL ropivacaine 0.75%
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Infraclavicular brachial plexus block with 20 mL ropivacaine 0.75%
Number of subjects: 120

Group type: COMPARATOR
Intervention: Axillary brachial plexus block with 20 mL ropivacaine 0.75%
Number of subjects: 120
Study: 24781895

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR) supplementation (210 mL, 19.5-mmol nitrate)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nitrate-free BR placebo (PL)
Number of subjects: 8
Study: 22562554

Group type: EXPERIMENTAL
Intervention: BAY 94‐8862 (2.5, 5, or 10 mg once daily)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: BAY 94‐8862 (2.5, 5, or 10 mg once daily or 5 mg twice daily)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Spironolactone (25-50 mg once daily)
Number of subjects: 420
Study: 20685688

Group type: EXPERIMENTAL
Intervention: Presence of signs of congestion (elevated jugular venous pressure, orthopnoea, ascites, or oedema)
Number of subjects: 2647

Group type: EXPERIMENTAL
Intervention: Signs of congestion
Number of subjects: 2647
Study: 18818161

Group type: EXPERIMENTAL
Intervention: Diacylglycerol (DAG)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Triacylglycerol (TAG)
Number of subjects: 5
Study: 16182674

Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts extended-release (MAS XR; Adderall XR(R)) 10, 20, and 30 mg
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts extended-release (MAS XR; Adderall XR(R)) 10 to 30 mg/day
Number of subjects: 580

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 580
Study: 12766930

Group type: EXPERIMENTAL
Intervention: Paroxetine 20mg mane
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mirtazapine 15mg/30mg nocte (comparator)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mirtazapine 15mg mane/15mg b.i.d. (verum)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10690136

Group type: EXPERIMENTAL
Intervention: dobutamine
Number of subjects: 22

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: dobutamine for low cardiac output
Number of subjects: 22
Study: 8932548

Group type: EXPERIMENTAL
Intervention: ofloxacin (400 mg twice a day for 5 doses)
Number of subjects: 9

Group type: COMPARATOR
Intervention: procainamide (1 g oral single dose)
Number of subjects: 9
Study: 1867179

Group type: EXPERIMENTAL
Intervention: Rifampin 300 mg twice daily for 5 days every 3 months
Number of subjects: 64

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Rifampin treatment
Number of subjects: 64
Study: 6732679

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31984508

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) treatment for 8 weeks, five sessions
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) treatment
Number of subjects: 10
Study: 30378323

Group type: EXPERIMENTAL
Intervention: Calcium alginate dressing
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vaseline gauze
Number of subjects: 40
Study: 27019511

Group type: EXPERIMENTAL
Intervention: Selective BRAF inhibitor (vemurafenib)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dabrafenib
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combined treatment (dabrafenib/trametinib)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dabrafenib (alone or in combination)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vemurafenib
Number of subjects: 24
Study: 24120464

Group type: EXPERIMENTAL
Intervention: Docetaxel with prednisone
Number of subjects: 0
Study: 22370330

Group type: EXPERIMENTAL
Intervention: Individual Meaning‐Centered Psychotherapy (IMCP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Therapeutic Massage (TM)
Number of subjects: 120
Study: 20398352

Group type: EXPERIMENTAL
Intervention: Anastrozole + Risedronate (A+R)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Anastrozole only (A)
Number of subjects: 213
Study: 18627623

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 17357850

Group type: EXPERIMENTAL
Intervention: Experimental condition with loud white-noise event (80 db) at fixed 120 s intervals during a 5-min EGM gambling session.
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control condition (no white noise).
Number of subjects: 69
Study: 14694352

Group type: EXPERIMENTAL
Intervention: 0.5 mg b.i.d. alprazolam
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 0.25 mg b.i.d. alprazolam
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 0.50 mg b.i.d. lorazepam
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 1.0 mg b.i.d. lorazepam
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 10969298

Group type: EXPERIMENTAL
Intervention: Propofol sedation at target plasma concentrations from 0.5 to 4.0 microgram/ml (group 1)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Propofol sedation at target plasma concentrations from 0.5 to 4.0 microgram/ml (group 2)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Propofol sedation at target plasma concentrations from 0.5 to 4.0 microgram/ml (group 3)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Propofol sedation at target plasma concentrations from 0.5 to 4.0 microgram/ml
Number of subjects: 69
Study: 9085317

Group type: EXPERIMENTAL
Intervention: Oral amiloride (10 mg of amiloride 1‐mg/ml solution)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Nebulized amiloride (4.5 ml of 1‐mg/ml solution in 12% saline)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Comparison of oral vs inhalation administration
Number of subjects: 19
Study: 8412202

Group type: EXPERIMENTAL
Intervention: 200 mg 4‐HPR daily for 52 weeks
Number of subjects: 137

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 137
Study: 3534992

Group type: EXPERIMENTAL
Intervention: Fluocortin butylester (FCB) 4 mg daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30649149

Group type: EXPERIMENTAL
Intervention: Cricoid pressure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 0
Study: 29173738

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 279